Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Optimal Induction and Re-Induction Regimens For Acute Myeloid Leukemia

79  Clofarabine with Topotecan, Vinorelbine, and Thiotepa (TVTC) in Children and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia

Kavitha Ramaswamy, et al.

The Abstract concludes: TVTC is an active regimen for children and young adults with relapsed/refractory AML, with an acceptable toxicity profile . Non-anthracycline containing salvage regimens are especially important as patients usually receive >400mg/m2 daunorubicin equivalents during frontline therapy. The majority of responders were successfully bridged to HSCT without exposure to additional anthracycline, with approximately half of these patients demonstrating long-term survival. TVTC warrants further exploration as a re-induction regimen in a larger cohort of patients with relapsed/refractory AML.

 

80  Characteristics and Outcome of Older Patients with Acute Promyelocytic Leukemia Front-Line Treated with or without Arsenic Trioxide - an International Collaborative Study

Sabine Kayser, et al.

The Abstract concludes: The ATO-based regimen for first line treatment of elderly APL pts was associated with excellent and sustained response rates. Our data demonstrate the important potential of ATO/ATRA in the primary management of older APL pts.

 

81  Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia (AML): Results from the Prospective Randomized AMLSG 09-09 Phase-III Study

Richard F. Schlenk, et al.

The Abstract concludes: The addition of GO to intensive induction therapy with ICE plus ATRA was associated with a higher death rate. In patients achieving a CR/CRi after induction therapy significantly less relapses occurred in the GO- compared to the standard-arm.

 

82  The Choice of Induction Regimen Affects Post Remission Survival of Acute Myelogenous Leukemia (AML) Patients with Intermediate or Poor Risk Disease

Melhem Solh, et al.

The Abstract concludes: This single center analysis shows that among patients with non-favorable risk AML, achieving CR after FLAG+/-Ida has better post remission survival than 3+7. This may be partially explained by the faster time to achieve CR and faster time to HSCT in the FLAG+/- Ida group.

 

83  Outcome at Two Years after a Response-Adapted Approach with Azacitidine and Intensive Chemotherapy in Patients > 60 Years with Newly Diagnosed AML Treated within the DRKS00004519 Trial of the East German Study Group (OSHO)

Nadia Jaekel, et al.

The Abstract concludes: Integrating an epigenetic therapy with IC in elderly pts with AML in an individualized response-based approach is feasible with low TRM and yields responses at least comparable to those achieved with repeated cycles of IC across all cytogenetic risk groups even in pts >70y. Most importantly, response could be translated into an improved survival particularly in pts with favorable and int-I risk genetics. Relapse remains high in adverse genetics. The results might further be improved through mutational profiling which allows the integration of emerging targeted therapies.

 

84  Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study

Nicholas J Short, et al.

The Abstract concludes: In older adults with newly diagnosed AML, DAC given for either 5 or 10 consecutive days resulted in similar response rates, early mortality and survival. No differences in response or survival were observed in any subgroup, including TP53-mutated AML.